Scotiabank raised the firm’s price target on Travere Therapeutics (TVTX) to $31 from $30 and keeps an Outperform rating on the shares. The company reported “impressive” results for Fislapri in IgA nephropathy, IgAN, in Q2, and the firm believes there are numerous reasons why this outperformance can continue, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $32 from $30 at Wedbush
- Travere Therapeutics Reports Strong Q2 2025 Growth
- Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics
- Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
- Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion